Bookmark
Forward
Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.
Robert Ettenger, Peter-Friedrich Hoyer, Paul Grimm, Nicholas Webb, Chantal Loirat, John D Mahan, Mark Mentser, Patrick Niaudet, Gisela Offner, R Vandamme-Lombaerts, J Mark Hexham, Everolimus Pediatric Study Group
Department of Pediatrics, Mattel Children's Hospital, University of California Los Angeles, Los Angeles, CA 90095-1752, USA. rettenger@mednet.ucla.edu
Pediatric transplantation 2008 Jun
Sizes of these terms reflect their relevance to your search.
There are few prospective clinical trials of mTOR inhibitors (or proliferation signal inhibitors) combined with CNI inhibitors in de novo pediatric renal transplantation. Results reported here are from a multicenter, open-label study in de novo pediatric renal transplant patients (patients received everolimus with cyclosporine and corticosteroids for one yr, then entered an extension study for a further two yr. Nineteen patients completed the one-yr study, of whom three discontinued study medication. Fifteen of the remaining 16 patients entered the extension study, eight of whom were aged <10 yr (Group 1) and seven were aged 10-16 yr (Group 2). Mean daily dose of everolimus during the first 36 months was 1.53 mg/m(2) BSA. Biopsy-proven acute rejection occurred in three patients in Group 2 and in one patient in Group 1. Biopsy-proven chronic allograft rejection was reported in four patients (two in each age group). Graft survival at one yr was 100%; one patient in Group 2 lost their graft subsequently during the extension. For patients entering the extension, patient survival at three yr was 100%. There were three cases of viral infection, including one case of cytomegalovirus infection. At three yr, mean total cholesterol was 5.5 +/- 0.8 mm/L (213 +/- 31 mg/dL) and four patients received statin therapy. Mean serum creatinine at 36 months was 96 +/- 36 microm/L (1.1 +/- 0.4 mg/dL). This is the first long-term prospective study to demonstrate that a regimen of everolimus, cyclosporine, and corticosteroids provides good efficacy, tolerability, and safety in de novo pediatric renal transplant patients.
Citation
Robert Ettenger, Peter-Friedrich Hoyer, Paul Grimm, Nicholas Webb, Chantal Loirat, John D Mahan, Mark Mentser, Patrick Niaudet, Gisela Offner, R Vandamme-Lombaerts, J Mark Hexham, Everolimus Pediatric Study Group.
Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year.
Pediatric transplantation.
2008 Jun;12(4):456-63
Mesh Tags
Adolescent
Adrenal Cortex Hormones
Biopsy
Child
Cyclosporine
Drug Therapy, Combination
Female
Graft Rejection
Graft Survival
Humans
Immunosuppressive Agents
Kidney Transplantation
Male
Sirolimus
Treatment Outcome
Substances
Adrenal Cortex Hormones
Immunosuppressive Agents
everolimus
Sirolimus
Cyclosporine
PMID: 18466433
View Full Text